| 1 |
A functional cellular framework for sex and estrous cycle-dependent gene expression and behavior
Joseph R. Knoedler, Sayaka Inoue, Daniel W. Bayless et al. · Cell
Open access |
21 Jan 2022 |
168 |
| 2 |
Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development
Yurong Lai, Xiaoyan Chu, Li Di et al. · Acta Pharmaceutica Sinica B
Open access |
17 Mar 2022 |
161 |
| 3 |
RNA-modifying proteins as anticancer drug targets
P. Ann Boriack‐Sjodin, Scott A. Ribich, Robert A. Copeland · Nature Reviews Drug Discovery
Review |
18 May 2018 |
159 |
| 4 |
The importance of binding kinetics and drug–target residence time in pharmacology
Kevin E. Knockenhauer, Robert A. Copeland · British Journal of Pharmacology
Open access |
10 May 2023 |
75 |
| 5 |
STIMULATION OF α7 CHOLINERGIC RECEPTORS INHIBITS LIPOPOLYSACCHARIDE-INDUCED NEUTROPHIL RECRUITMENT BY A TUMOR NECROSIS FACTOR α-INDEPENDENT MECHANISM
Ida A. J. Giebelen, David J. van Westerloo, Gregory J. LaRosa et al. · Shock
|
15 Mar 2007 |
67 |
| 6 |
Co-opting the E3 ligase KLHDC2 for targeted protein degradation by small molecules
Christopher M. Hickey, Katherine Marie Digianantonio, Kurt Zimmermann et al. · Nature Structural & Molecular Biology
|
4 Jan 2024 |
62 |
| 7 |
Evolution of the drug-target residence time model
Robert A. Copeland · Expert Opinion on Drug Discovery
|
Jul 2021 |
61 |
| 8 |
Enzyme–Inhibitor Interactions and a Simple, Rapid Method for Determining Inhibition Modality
Shane M. Buker, P. Ann Boriack‐Sjodin, Robert A. Copeland · SLAS DISCOVERY
Open access |
27 Feb 2019 |
56 |
| 9 |
A Mass Spectrometric Assay of METTL3/METTL14 Methyltransferase Activity
Shane M. Buker, Zachary A. Gurard‐Levin, Benjamin D Wheeler et al. · SLAS DISCOVERY
Open access |
5 Oct 2019 |
47 |
| 10 |
Novel irreversible covalent BTK inhibitors discovered using DNA-encoded chemistry
John P. Guilinger et al. · Bioorganic & Medicinal Chemistry
Open access |
19 May 2021 |
46 |
| 11 |
Mechanism for DPY30 and ASH2L intrinsically disordered regions to modulate the MLL/SET1 activity on chromatin
Young‐Tae Lee, Alex M. Ayoub, Sang‐Ho Park et al. · Nature Communications
Open access |
19 May 2021 |
45 |
| 12 |
A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair
Jennifer Castro et al. · Cancer Research
Open access |
26 Nov 2024 |
20 |
| 13 |
INTRAPULMONARY DELIVERY OF ETHYL PYRUVATE ATTENUATES LIPOPOLYSACCHARIDE- AND LIPOTEICHOIC ACID-INDUCED LUNG INFLAMMATION IN VIVO
Marieke A. D. van Zoelen, Alex F. de Vos, Gregory J. LaRosa et al. · Shock
|
22 Jun 2007 |
19 |
| 14 |
Targeting kinases with precision
Alexandra K. Gardino, Erica K. Evans, Joseph L. Kim et al. · Molecular & Cellular Oncology
Open access |
28 Mar 2018 |
18 |
| 15 |
Crystal structures of the DExH-box RNA helicase DHX9
Young‐Tae Lee, E. Allen Sickmier, Simina Grigoriu et al. · Acta Crystallographica Section D Structural Biology
Open access |
20 Oct 2023 |
12 |
| 16 |
Discovery of ATX968: An Orally Available Allosteric Inhibitor of DHX9
Matthew H. Daniels et al. · Journal of Medicinal Chemistry
Open access |
29 Apr 2025 |
10 |
| 17 |
Development of assays to support identification and characterization of modulators of DExH-box helicase DHX9
Deepali Gotur, April W. Case, Julie X. Liu et al. · SLAS DISCOVERY
Open access |
23 Aug 2023 |
7 |
| 18 |
N-Functionalization of 1,2-Azaborines
Shih‐Yuan Liu, Hyelee Lee, Marisol Sarmiento Alvarado et al. · Synlett
Open access |
12 Jun 2023 |
7 |
| 19 |
Discovery of Kinesin KIF18A Inhibitor ATX020: Tactical Application of Silicon Atom Replacement
Brian A. Sparling, Hyelee Lee, Mary-Margaret Zablocki et al. · ACS Medicinal Chemistry Letters
|
27 Oct 2025 |
5 |
| 20 |
The KIF18A Inhibitor ATX020 Induces Mitotic Arrest and DNA Damage in Chromosomally Instable High-Grade Serous Ovarian Cancer Cells
Jayakumar R. Nair, Tzu‐Ting Huang, Maureen M. Lynes et al. · Cells
Open access |
26 Nov 2025 |
4 |
| 21 |
Establishing and Maintaining a Robust Sample Management System
William P. Janzen, Elizabeth A. Admirand, Jeffery Andrews et al. · SLAS TECHNOLOGY
Open access |
13 Mar 2019 |
4 |
| 22 |
Characterization of exoribonuclease XRN1 as a cancer target and identification of adenosine-3’,5’-bisphosphate as a potent enzyme inhibitor
G.J. Lockbaum et al. · Communications Biology
Open access |
9 Apr 2025 |
3 |
| 23 |
Chance Favors the Perplexed Mind: The Critical Role of Mechanistic Biochemistry in Drug Discovery
Robert A. Copeland · Biochemistry
|
14 Jul 2021 |
3 |
| 24 |
DHX9 Inhibition Enhances Paclitaxel Sensitivity by Inducing Mitotic Failure in Ovarian and Endometrial Cancers
Tzu‐Ting Huang, Jayakumar R. Nair, Courtney Bowen et al. · Molecular Cancer Therapeutics
Open access |
24 Mar 2026 |
1 |
| 25 |
The neural mechanisms supporting the rise and fall of maternal aggression
Takashi Yamaguchi, Rongzhen Yan, Muhammad Amir Khan et al. · Nature
Open access |
15 Apr 2026 |
1 |
| 26 |
MLL1 Methyltransferase Activity is Regulated by Distinct Nucleosome Binding Modes
Alex M. Ayoub, Sang Ho Park, Young‐Tae Lee et al. · bioRxiv (Cold Spring Harbor Laboratory)
PreprintOpen access |
13 Apr 2021 |
1 |
| 27 |
Rebuttal to Response to the Article “Enzyme–Inhibitor Interactions and a Simple, Rapid Method for Determining Inhibition Modality”
Robert A. Copeland · SLAS DISCOVERY
Open access |
12 Sep 2019 |
1 |
| 28 |
A first-in-human study of ATX-295, an oral inhibitor of KIF18A, in patients with advanced or metastatic solid tumors, including ovarian cancer.
Judy S. Wang, Ildefonso I. Rodriguez Rivera, Deepak Bhamidipati et al. · Journal of Clinical Oncology
Open access |
28 May 2026 |
0 |
| 29 |
Monitoring Mouse Surface Temperature During Stress with a Thermal Camera: A Low‐Cost Infrared Videography System for Evaluating Murine Metabolism
B. S. Page, Carolina Cora, James T. Reilly et al. · Current Protocols
Open access |
Feb 2025 |
0 |
| 30 |
Discovery and Development of Tazemetostat
Peter T. C. Ho, Robert A. Copeland
Book chapter |
30 Sep 2024 |
0 |
| 31 |
RNA Modifying Proteins: Emerging Targets for Drug Discovery
P. Ann Boriack‐Sjodin, Serena J. Silver
Book chapter |
30 Sep 2024 |
0 |
| 32 |
Evaluation of membrane type 1 metalloproteinase (MT1-MMP/MMP14) expression as a prognostic biomarker in patients with solid tumours screened for a Phase I/II trial
Niamh Peters, H. Morley, S. Khalique et al. · European Journal of Cancer
Open access |
Oct 2022 |
0 |